Literature DB >> 17157597

Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration.

Ulrich H M Spandau1, Jost B Jonas.   

Abstract

PURPOSE: To report on the development of retinal pigment epithelium tears after intravitreal injections of bevacizumab as treatment of exudative age-related macular degeneration (AMD).
DESIGN: Interventional case series.
METHODS: The study included 63 patients who received an intravitreal injection of 1.5 mg bevacizumab as treatment of a detachment of the retinal pigment epithelium attributable to AMD and who had a follow-up of at least two months.
RESULTS: Four patients (6%) developed a tear of the retinal pigment epithelium in the parafoveal region. Compared with the baseline value, visual acuity at the end of follow-up remained stable in three patients and declined in the fourth patient.
CONCLUSIONS: Intravitreal injections of bevacizumab may be followed by a tear of the retinal pigment epithelium in eyes with exudative AMD and a retinal pigment epithelium detachment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157597     DOI: 10.1016/j.ajo.2006.06.048

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  16 in total

1.  Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).

Authors:  David Sarraf; Anthony Joseph; Ehsan Rahimy
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

3.  Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD.

Authors:  M Gutfleisch; B Heimes; M Schumacher; M Dietzel; A Lommatzsch; A Bird; D Pauleikhoff
Journal:  Eye (Lond)       Date:  2011-06-24       Impact factor: 3.775

4.  Retinal pigment epithelial tear after intravitreal bevacizumab injection for exudative age-related macular degeneration.

Authors:  Sunil Kumar Singh; Satyen Deka
Journal:  Oman J Ophthalmol       Date:  2014-05

5.  Age-related macular degeneration: current treatments.

Authors:  Jean Pierre Hubschman; Shantan Reddy; Steven D Schwartz
Journal:  Clin Ophthalmol       Date:  2009-06-02

6.  Intravitreal bevacizumab: an analysis of the evidence.

Authors:  Derrick P Smit; David Meyer
Journal:  Clin Ophthalmol       Date:  2007-09

7.  Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration.

Authors:  Jaime Levy; Marina Shneck; Shirley Rosen; Itamar Klemperer; David Rand; Orly Weinstein; Anry Pitchkhadze; Nadav Belfair; Tova Lifshitz
Journal:  Int Ophthalmol       Date:  2008-06-11       Impact factor: 2.031

8.  Spontaneous or secondary to intravitreal injections of anti-angiogenic agents retinal pigment epithelial tears in age-related macular degeneration.

Authors:  Pia E Leon; Sandro Saviano; Andrea Zanei; Marco R Pastore; Elvira Guaglione; Alessandro Mangogna; Daniele Tognetto
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

9.  [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors:  D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

10.  Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.

Authors:  Saad Shaikh; John C Olson; Preston P Richmond
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.